Skip to main content
Erschienen in: Reactions Weekly 1/2023

01.05.2023 | Case report

Chloroquine/lopinavir/ritonavir

Drug (lopinavir) plasma concentration increased following drug interaction and off-label use: 11 case reports

Erschienen in: Reactions Weekly | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Excerpt

Author Information
An event is serious (based on the ICH definition) when the patient outcome is: Drug interaction
  • * death
  • * life-threatening
  • * hospitalisation
  • * disability
  • * congenital anomaly
  • * other medically important event
Literatur
Zurück zum Zitat Naghani SM, et al. Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19. European Journal of Hospital Pharmacy - Science and Practice 30: e106-e108, Mar 2023. Available from: URL: http://doi.org/10.1136/ejhpharm-2020-002596 Naghani SM, et al. Crushing lopinavir/ritonavir tablets does not result in lower exposure to lopinavir/ritonavir in adult patients with COVID-19. European Journal of Hospital Pharmacy - Science and Practice 30: e106-e108, Mar 2023. Available from: URL: http://​doi.​org/​10.​1136/​ejhpharm-2020-002596
Metadaten
Titel
Chloroquine/lopinavir/ritonavir
Drug (lopinavir) plasma concentration increased following drug interaction and off-label use: 11 case reports
Publikationsdatum
01.05.2023
Verlag
Springer International Publishing
Erschienen in
Reactions Weekly / Ausgabe 1/2023
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI
https://doi.org/10.1007/s40278-023-39266-2

Weitere Artikel der Ausgabe 1/2023

Reactions Weekly 1/2023 Zur Ausgabe

Case report

Sintilimab

Case report

Mercaptopurine

Case report

Linagliptin

Case report

Multiple drugs

Case report

Selpercatinib